Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Study finds early-onset Parkinson’s burden has more than doubled worldwide

1

Jul 2026

Study finds early-onset Parkinson’s burden has more than doubled worldwide

A GBD 2021 analysis of 204 countries and territories found that early-onset Parkinson’s disease burden among people aged 20 to 49 more than doubled from 1990 to 2021. Age-standardized incidence, prevalence, and disability rates rose globally, with higher estimated burden among males, rapid growth in middle and high-middle SDI regions, and moderate ecological correlations with pesticide use.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.